FDA Influenced Decision Not to Send Alert on Postvaccination Heart Inflammation: Emails

Regulators met with counterparts from the U.S. Centers for Disease Control and Prevention.

The U.S. Food and Drug Administration (FDA) in White Oak, Md., on June 5, 2023. Madalina Vasiliu/The Epoch Times

U.S. drug regulators influenced the decision not to send an alert on heart inflammation cases that were appearing after COVID-19 vaccination, according to emails obtained through the Freedom of Information Act (FOIA).

The U.S. Centers for Disease Control and Prevention (CDC) was preparing to issue an alert about postvaccination myocarditis, or heart inflammation, through its Health Alert Network in May 2021. But that plan changed after meeting with the U.S. Food and Drug Administration (FDA), according to the emails.